Cited by 134Epigenetics and DNA MethylationTreatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

The potential of SLC6A4 gene methylation analysis for the diagnosis and treatment of major depression

Open access
Okada, Satoshi, Morinobu, Shigeru, Fuchikami, Manabu, Segawa, Masahiro, Yokomaku, Kana, Kataoka, Tsutomu, Okamoto, Yasumasa, Yamawaki, Shigeto +7 more·2014·Journal of Psychiatric Research

Abstract

We examined the utility of DNA methylation profiles at the CpG island of SLC6A4 (DMS) as a diagnostic biomarker for major depression (MD). In addition, the relationship between DMS and the serotonin transporter gene-linked polymorphic region (5-HTTLPR) allele, the severity of symptoms, number of early adversities, and therapeutic responses to antidepressants were examined. Genomic DNA was extracted from peripheral blood of Japanese healthy controls and patients with MD before and after treatment. DMS was analyzed using a MassARRAY Compact System. The severity of depression was evaluated using the Hamilton Rating Scale for Depression, and early adversity was evaluated using the Early Trauma Inventory. We were unable to distinguish between and healthy controls, or between unmedicated patients and medicated patients using DMS. The 5-HTTLPR allele had no significant effect on DMS. The methylation rates for several CpGs differed significantly after treatment. Notably, the methylation rate of CpG 3 in patients with better therapeutic responses was significantly higher than that in patients with poorer responses. Although further studies examining the function of specific CpG units of SLC6A4 are required, these results suggest that the pre-treatment methylation rate of SLC6A4 is associated with therapeutic responses to antidepressants in unmedicated patients with MD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jpsychires.2014.02.002

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SSRIs may normalize some of these methylation changes.

    “SSRIs may normalize some of these methylation changes”

    From The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry (2025) · cites this paper as [106]

    The Discussion reports that CpG 3 methylation changed after antidepressant treatment, supporting a possible treatment-related effect. But Table 2 shows that CpG 3 moved away from the healthy-control level, not toward it, and the treatment group included milnacipran as well as SSRIs. The paper therefore does not establish that SSRIs normalize these changes; page numbers are unavailable in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • SLC6A4 methylation can be used as an indicator of treatment response to SSRIs or psychotherapy.

    “SLC6A4 methylation can be used as an indicator of treatment response to SSRIs or psychotherapy”

    From The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry (2025) · cites this paper as [106]

    The Results section reports that pretreatment methylation at SLC6A4 CpG 3 correlated with response after six weeks of antidepressant treatment, which included SSRIs. The Discussion describes this as a possible marker, not an established indicator, and the paper does not report psychotherapy response (page numbers unavailable). (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Methylation at a certain CpG site within SLC6A4 is significantly increased in patients with better therapeutic responses compared to those with worse responses.

    “Methylation at a certain CpG site within SLC6A4 is significantly increased in patients with better therapeutic responses compared to those with worse responses.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Bremner JD, Vermetten E, Mazure CM. Development and preliminary psychometric properties of an instrument for the measurement of childhood trauma: the Early Trauma Inventory. Depress Anxiety 2000; 12(1): 1-12.

Cited by

Sorted by citations

Authors
Okada, S., Morinobu, S., Fuchikami, M., Segawa, M., Yokomaku, K., Kataoka, T., Okamoto, Y., Yamawaki, S., Inoue, T., Kusumi, I., Koyama, T., Tsuchiyama, K., Terao, T., Kokubo, Y., & Mimura, M.
Affiliations
  • Hiroshima University (JP)
  • Hokkaido University (JP)
  • Oita University (JP)
  • SHOWA Medical University (JP)
Corresponding author
Morinobu, Shigeru
Venue
Journal of Psychiatric Research
Publisher
Elsevier BV
Published
2014-06
Volume
53
Pages
47-53
ISSN
0022-3956 (ISSN-L)
OpenAlex
W2035269052
Cited by
125
References
48
Citations by year
2026: 2 · 2025: 9 · 2024: 9 · 2023: 10 · 2022: 13 · 2021: 37 · 2020: 8 · 2019: 8 · 2018: 4 · 2017: 9 · 2016: 9 · 2015: 7
FWCI
3.42
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychiatric Research (acceptedVersion)
  • PubMed (publishedVersion)
  • Hiroshima University Acedemic Information Repository (Hiroshima University) (submittedVersion)
Funders
  • Core Research for Evolutional Science and Technology
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Science and Technology Agency
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
serotonin transporter, DNA methylation, major depressive disorder, diagnostic biomarkers, antidepressant response, 5-HTTLPR, CpG islands, childhood adversity, depression severity, epigenetics
MeSH terms
Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Female, Genotype, Humans, Male, Middle Aged, Pharmacogenetics, Psychiatric Status Rating Scales, Statistics as Topic, Case-Control Studies, CpG Islands, DNA Methylation, Serotonin Plasma Membrane Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review